HydRegen raises $8M Series A to swap precious metals for enzymes in chemical plants
What's the deal? HydRegenDealroom has a profile for this one. Try Dealroom →, a UK biotechnology company, has closed £6 million ($8 million) in the first close of its Series A. Genoa VenturesDealroom has a profile for this one. Try Dealroom → led the round, with participation from Clean Growth FundDealroom has a profile for this one. Try Dealroom → and First Imagine! VenturesDealroom has a profile for this one. Try Dealroom →. Oxford Technology Management, Headington Holdings, Oxonian, Foxglove Capital, and Rapid Innovation Group also joined.
What's the endgame? HydRegen replaces precious-metal catalysts with enzyme-based alternatives for hydrogenation, a step essential to 14 to 20% of all processes in the trillion-dollar industrial chemicals market. It produces a hydrogenase enzyme through fermentation, then formulates it into catalyst platforms that run hundreds of different reactions. The company says the approach makes manufacturing up to 40% more cost-effective while lowering carbon emissions.
Why now? Conventional precious-metal processes are energy-intensive and harder to operate under tightening environmental rules. HydRegen pitches its catalysts as a "drop-in" to existing infrastructure, where they can turn over millions of times without forcing customers to rebuild plants.
What's the money for? The funding will expand work with existing pharmaceutical and specialty chemical customers while pushing into agrochemicals, materials, and bulk chemicals. The goal is to take the platform into higher-volume markets.
"Manufacturers can change the catalyst without changing the factory," said Holly Reeve, chief executive officer and co-founder of HydRegen.
The signal: Investors are hunting for biomanufacturing plays that pencil out economically rather than requiring massive upfront infrastructure. "Too often the capital journey doesn't pencil out," said Jenny Rooke, founder and managing director of Genoa Ventures, pointing to scale-up costs and unproven unit economics. At £6 million, HydRegen's round sits in the mid-tier of deals by size — a measured bet on biology closing the gap with industrial chemistry.
Read more: finanznachrichten.de
Image credit: USDAgov
